CONMED Acquires Biorez, Inc.

CONMED Corporation Acquires In2Bones Global, Inc.

June 13, 2022

Medical Devices

CONMED Corporation has completed its acquisition of privately-held In2Bones Global, Inc., a Memphis-based developer, manufacturer and distributor of medical devices for upper- and lower-extremity (hand, wrist, elbow, foot and ankle) care. The transaction was financed with proceeds from CONMED's convertible notes, borrowings under its amended credit facility and cash on hand.

Bioventus Acquires Bioness, Inc.

March 30, 2021

Medical Devices

Bioventus Inc. acquired Bioness, Inc. for $45 million in up-front consideration plus up to $65 million of contingent consideration, making Bioness a wholly‑owned subsidiary. The acquisition expands Bioventus' rehabilitation and neuromodulation product portfolio and R&D pipeline, and is expected to be accretive to revenue by leveraging Bioventus' global commercial infrastructure.

Merit Medical Systems Acquires Biolife Delaware

May 28, 2025

Medical Devices

Merit Medical Systems has acquired Biolife Delaware, a Sarasota, Florida-based maker of StatSeal and WoundSeal hemostatic devices, in a cash transaction valued at approximately $120 million (including assumed liabilities). The deal expands Merit's hemostasis and wound-care product portfolio and is expected to modestly impact 2025 non-GAAP profitability while enhancing Merit's ability to serve a broad set of percutaneous procedure end markets.

Medix Biochemica Group Acquires Bioresource Technology (BRT)

June 21, 2022

Biotechnology

Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.